Document is current
Any future updates will be listed below
-
Authors
Roos Alexander, Hanna
Afrin Ruma, Shamima
Jain, Shruti
Lundin, Eva
Liv, Per
Israelsson, Pernilla
Pettersson, Kim
Idahl, Annika
-
Funding
Funding for this research was provided by:
Umea University
- License Information
-
More Information
Article History
Received: 28 January 2026
Accepted: 18 May 2026
First Online: 29 May 2026
Declarations
:
: This study was approved by the Regional Ethical Review Authority in Umeå, Dnr. 2017-376-31. Prior to diagnosis and following the obtaining of informed consent, patients who were subsequently diagnosed with ovarian cancer prospectively donated plasma samples.
: The blood samples were collected at health care facilities in the Västerbotten county of Sweden, as part of a health-intervention program between 1990 and 2017. Individuals who were subsequently diagnosed with ovarian cancer and controls, prospectively donated plasma samples following the obtaining of informed consent to use samples and data in research. Prior to each new study using samples and data the ethical review authority has to approve of the research. New individual consent for each study and publication is therefore not needed according to Swedish law.
: Conflicts of interest Kim Petterson is the co-inventor of an invention relating to the determination of the CA125 MGL glycovariant. Other authors declare no potential conflicts of interest.
